相似文献
1
Infliximab treatment for rheumatic disease: clinical and radiological efficacy.
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii67-9. doi: 10.1136/ard.61.suppl_2.ii67.
2
The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Arthritis Rheum. 2008 Feb 15;59(2):234-40. doi: 10.1002/art.23333.
3
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Ann Rheum Dis. 2008 May;67(5):710-2. doi: 10.1136/ard.2007.081513. Epub 2007 Dec 13.
4
[Autoimmune aspects of treatment with TNF-alpha inhibitors].
Postepy Hig Med Dosw (Online). 2007 Aug 28;61:478-84.
5
Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients.
Rheumatol Int. 2012 Sep;32(9):2769-75. doi: 10.1007/s00296-011-2017-5. Epub 2011 Aug 7.
6
Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
Joint Bone Spine. 2012 Oct;79(5):457-63. doi: 10.1016/j.jbspin.2011.10.001. Epub 2011 Nov 15.
7
[Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Presse Med. 2009 May;38(5):774-87. doi: 10.1016/j.lpm.2009.02.003. Epub 2009 Mar 26.
8
The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Int J Rheum Dis. 2009 Jul;12(2):118-24. doi: 10.1111/j.1756-185X.2009.01393.x.
9
[Biologicals in the treatment of rheumatic diseases].
Dtsch Med Wochenschr. 2006 Oct 13;131(41):2279-85. doi: 10.1055/s-2006-951364.
10
引用本文的文献
1
Tumor Necrosis Factor-Alpha Antagonist Interferes With the Formation of Granulomatous Multinucleated Giant Cells: New Insights Into Infection.
Front Immunol. 2019 Aug 14;10:1947. doi: 10.3389/fimmu.2019.01947. eCollection 2019.
2
Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients.
Arthritis Res Ther. 2015 Aug 11;17(1):203. doi: 10.1186/s13075-015-0719-x.
3
[Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy].
Z Rheumatol. 2011 Nov;70(9):775-89. doi: 10.1007/s00393-011-0870-y.
4
Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.
Clin Rheumatol. 2008 Apr;27(4):491-6. doi: 10.1007/s10067-007-0738-3. Epub 2007 Oct 19.
5
Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.
Br J Pharmacol. 2007 Apr;150(7):862-72. doi: 10.1038/sj.bjp.0707165. Epub 2007 Feb 26.
6
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
Arthritis Res Ther. 2006;8(1):R3. doi: 10.1186/ar1851.
7
Rheumatoid arthritis as a hyper-endoplasmic-reticulum-associated degradation disease.
Arthritis Res Ther. 2005;7(5):181-6. doi: 10.1186/ar1808. Epub 2005 Aug 17.
8
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Ann Rheum Dis. 2004 Oct;63(10):1218-21. doi: 10.1136/ard.2003.014647.
9
Biologic agents for the treatment of juvenile rheumatoid arthritis: current status.
Paediatr Drugs. 2004;6(3):137-46. doi: 10.2165/00148581-200406030-00001.
10
Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis.
Clin Exp Immunol. 2004 Apr;136(1):21-9. doi: 10.1111/j.1365-2249.2004.02402.x.
本文引用的文献
1
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum. 2002 Jun;46(6):1451-9. doi: 10.1002/art.10302.
2
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
Lancet. 2002 Apr 6;359(9313):1187-93. doi: 10.1016/s0140-6736(02)08215-6.
3
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
Arthritis Rheum. 2002 Mar;46(3):755-65. doi: 10.1002/art.511.
4
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.
Ann Rheum Dis. 2002 Mar;61(3):207-12. doi: 10.1136/ard.61.3.207.
5
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.
Lancet. 2001 Jun 9;357(9271):1842-7. doi: 10.1016/s0140-6736(00)04954-0.
6
Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.
Br J Dermatol. 2001 Mar;144(3):587-9. doi: 10.1046/j.1365-2133.2001.04089.x.
7
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
N Engl J Med. 2000 Nov 30;343(22):1594-602. doi: 10.1056/NEJM200011303432202.
8
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Lancet. 2000 Jul 29;356(9227):385-90. doi: 10.1016/S0140-6736(00)02530-7.
9
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
Arthritis Rheum. 2000 Jun;43(6):1346-52. doi: 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E.
10
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
Ann Rheum Dis. 2000 Jun;59(6):428-33. doi: 10.1136/ard.59.6.428.
Zotero 插件